Transmission electron microscope imaging: After treated with PA, the cell samples were fixed in the fresh 2.5% glutaraldehyde for 5 h at 4°C and post-fixed in 1% osmium tetroxide for 1.5 h. Then the samples were dehydrated in a gradient ethanol series and infiltrated with Epon812. The samples were embedded and cured at 37°C for 12 h, 45°C for 12 h and 60°C for 24 h. Ultrathin sections were cut using Leica EM UC7 and uranyl acetate and lead citrate were used to stain the section before the observation.
Cell imaging: Fluorescent images were acquired with confocal laser scanning microscope with an objective lens (× 40/60). The excitation wavelengths and emission wavelengths, which were fit in different dyes, were described in paper. PC9 and H1650 cells were planted on Petri-dishes (Φ = 20 mm) and allowed to adhere for 24 h before the treatments. The prodrugs and commercial dyes were added to the culture plates which were filled with 1 mL fresh complete medium.
Flow cytometry analysis: PC9 cells and H1650 cells were plated into 2.0 × 10 5 cells/well in 6-well plates. After incubating the cells at 37°C with 5% CO2 for 1-2 days to reach 80% confluency, the medium was added the compounds. At the end of incubation, the cells were dissociated and washed to stain. We used an FITC Annexin V Apoptosis Detection Kit (BD Biosciences, USA) to detect the apoptosis with the treatment of different prodrugs. These samples were detected by FITC channel and PE channel using FACSAria. The procedure of detecting the changes of p-Akt (Ser473) was similar before being washed. The dissociated cells were resuspended by stain buffer (BD Biosciences, USA) and fixed by fixation buffer (BD Biosciences, USA). After being washed by stain buffer for 3 times, the cells were treated by perm buffer III (BD Biosciences, USA). Then the cells were stained by PE mouse anti-Akt (pS473) and relative isotype control (BD Biosciences, USA) to evaluate the level of phosphorylation of the cells through FACSAria (BD Biosciences, USA).
Mice:
All animal experiments were performed in accordance with the guidelines established by the Committee of Animal Research Policy of Binzhou Medical University. 5-week-old female specific pathogen free (SPF) athymic nude mice and BALB/c mice were obtained from Changzhou Cavens Lab Animal Co. Ltd. The animals were housed in individual ventilated cages and fed a SPF laboratory diet and water ad libitum. 2 × 10 6 cells were suspended in media and implanted subcutaneously into nude mice.
Histological experiments: Lungs and tumors from nude mice were excised. The tissues were fixed in 10% formaldehyde and embedded in paraffin. Then the paraffin masses were cut and dewaxed. The sections were dehydrated using graded ethanol series and washed by ultrapure water. The lung sections were stained with hematoxylin and eosin to observe the pulmonary tissue structure. Immunofluorescence staining followed the dehydration. After being treated with Trition X-100 and serum, the sections were stained by Ki-67 (D3B5) Rabbit mAb (Alexa Fluor® 647 Conjugate) (Cell Signaling Technology, USA) overnight. The sections were stained by DAPI to display the nucleus and enveloped by glycerol before observation.
Imaging mice in vivo:
A In-vivo Imaging System was employed to image nude mice treated by TPG, TBG or Probe-PA. The excitation and emission wavelengths were chosen as described in paper. The mice were anesthetized prior to injection and during imaging. After in vivo imaging, the organs (lung, heart, liver, kidney and spleen) and tumors were excised to perform ex vivo imaging.
Patient samples: TBLB tissues were obtained from Department of Respiratory Medicine, Affiliated Hospital of Binzhou Medical University. CT scanning was taken before TBLB to ensure the suspected locations. Informed written consents were provided by all patients. The experiments were approved by the Ethics Committee of Binzhou Medical University.
Cancer cells detection of clinical tissues:
The TBLB tissues were separated under the direct vision and placed into 10 mL cold Hank's Balanced Salt Solution (HBSS) (Gibco, USA). The tissues were cut into pieces as small as possible and washed three times by HBSS. 200 U/mL type I collagenase (Gibco, USA) HBSS solution were made and heated to 37°C. The small tissues were placed into the collagenase solution at 37°C for 3 h, in order to obtain the single cell suspension. The screen mesh was used to filter the cell masses and the collagenase was discarded by centrifuge. The cells were washed by PBS three times and treated by FACS Lysing Solution (BD Bioscience, USA). The cells were washed three times and counted to suspend by 1 mL RMPI-1640 medium. 5 μM TPG was added into the single cell suspension to stain for 15 min at 37°C. After being washed by PBS twice, the cells were treated by ice ethanol at -20°C overnight. At the end of last procedure, CEA Antibody, FITC (CI-P83-1) (Invitrogen, USA) and Cytokeratin 19 Monoclonal Antibody (A53-B/A2), Alexa Fluor 488 (Invitrogen, USA) were used to stain the cells for 30 min. After being washed three times, the cells were counted and tested with flow cytometry with a collection of 10 4 cells.
Statistical analysis:
Statistical Product and Service Solutions (SPSS) software 19.0 was used for the statistical analysis. The error bars shown in the figures represented the mean ± s.d. Differences were determined with a one-way, two-way analysis of variance (ANOVA) followed by LSD test. Differences between two groups were assessed by using the Student's t-tests. Statistical significance was assigned at * P < 0.05, ** P < 0.01. Sample size was chosen empirically based on our previous experiences and pretest results. No statistical method was used to predetermine sample size and no data were excluded. The numbers of animals or samples in every group were described in the corresponding figure legends. The distributions of the data were normal. All experiments were done with at least three biological replicates. Experimental groups were balanced in terms of animal age, sex and weight. Animals were all caged together and treated in the same way. Appropriate tests were chosen according to the data distribution.
Variance was comparable between groups in experiments described throughout the manuscript.
Investigator was not blinded to the group allocation during the experiment or to outcome assessments. No randomization was used to allocate animals to experimental groups.
Synthesis and Characterization of Compounds
Scheme S1 The synthesis routes of PPG and TPG.
Synthesis of Compound 1. The Gefitinib (0.116 g, 0.26 mmol) was dissolved into 100 mL dichloromethane (DCM) in an ice bath. When the tiphosgene (1.539 g, 5.2 mmol) was dissolved into the solution, N,N-diisopropylethylamine (DIPEA) (1.006 g, 7.8 mmol) in 10 mL DCM was dropwise added into the mixture. At the end of the process of dropping, the mixture was heated at room temperature for 3 h under argon atmosphere. The mixture was evaporated to obtain yellow solid and dropped into an anhydrous tetrahydrofuran (THF) solution containing 2-hydroxyethyl disulfide (0.200 g, 1.3 mmol), triethylamine (0.788 g, 0.78 mmol) and 4-dimethylaminopyridine (DMAP) (catalytic) at 0°C under argon atmosphere. The reaction was stirred for 72 h at 0°C and stopped by adding water to the mixture. After evaporated, re-dissolved solvent with 200 mL DCM was washed by brine (200 mL × 3). The organic layer was dried by sodium sulphate and filtered. The solvent was evaporated and purified by silica gel column chromatography using DCM/MeOH (30:1, v/v) as eluent to afford Compound 1 (0.101 g, yield: 62%) as yellow white solid. 
Synthesis of Prodrug Polyamine Analogue-Gefitinib (PPG).
The synthesis route of PA was reported by the previous work. 
Synthesis of Theranostics Polyamine Analogue-Gefitinib (TPG).
The synthesis route of azo-BODIPY was reported by the previous work. 3 Compound 1 (0.194 g, 0.31 mmol) and triphosgene (1.835 g, 6.2 mmol) were dissolved in a 250 mL round bottom flask with 100 mL DCM and DIPEA (1.200 g, 9.3 mmol) was dropped into the solution under argon atmosphere at ice bath. The reaction was stirred for 3 h at room temperature and the solvent was evaporated. The re-dissolved solvent with 10 mL DCM was added dropwise into the 50 mL DCM solution containing DIPEA (0.040 g, 0.31 mmol) and azo-BODIPY (0.132 g, 0.25 mmol) under argon atmosphere at room temperature. The reaction was stirred for 36 h at room temperature and was stopped with adding water. The crude was extracted with DCM (200 mL × 3) and brine (200 mL × 3) and the organic layer was dried with sodium sulphate for 8 h. 
3.
Mechanism of PPG releasing Gefitinib Figure S1 . Mechanism of Gefitinib released by the reaction between GSH and prodrugs. Figure S2 . Mechanism of Gefitinib released and NIR fluorescence emitting by the reaction between GSH and TPG. 
4.

Mechanism of TPG releasing Gefitinib and emitting NIR fluorescence
Spectral properties and selectivity of TPG towards GSH
Reaction kinetics of prodrug and GSH monitored by HPLC.
In order to verify that prodrug (PPG) could release Gefitinib without the interference of azo-BODIPY. We carried out the inspection of reaction kinetics between prodrug and GSH by reversedphase high performance liquid chromatography (RP-HPLC). Samples were separated on RP-HPLC with a ZORBAX SB-C18 column (4.6×150 mm, 5 μm), acetonitrile/0.15% (v/v) ammonium acetate (adjusted pH 8.0 with ammonium hydroxide) =(85:15, v/v) as mobile phase at a flow rate of 1.0 mL/min, detection wavelength of 310 nm and column temperature of 37°C, injection volume: 20 µL. GSH (10 mM) was used to cleave the disulfide of prodrug (10 μM). As shown in Figure S4a , the peak of PPG appeared at 2.06 min when the reaction started. The peak at 2.41 min representing Gefitinib gradually rose. The reaction stopped at the end of 17 h. This indicated a consistent result of spectral dynamics. As shown in Figure S4b , the cumulative release of PPG was further quantified according to HPLC in Figure  S4a . Figure S12 . Organ targeting of Probe-PA in vivo and ex vivo. BALB/c mice were injected via tail vein with a single-dose 0.2 mL of Probe-PA (1 mM) (DMSO/saline 1:1/v/v) and imaging after 2, 4 and 6 h. Separated organs (lung, heart, liver, kidney, spleen) of the mice were also imaged.
Images of TPG in cysteine treated PC9 cells and H1650 cells
The investigation of TPG transmembrane transport with corresponding ligand
Organ targeting of Probe-PA in vivo and ex vivo
Fluorescence distribution of TPG and TBG in PC9 and H1650 tumor
The fluorescent images were used to prove the fluorescence distribution of TPG and TBG in PC9 and H1650 tumor mass. The mice were from those bearing PC9 and H1650 tumors used for efficacy evaluation in vivo. The fluorescence mainly accumulated in the tumor tissue, which indicated the drug release occurred in the cell cytoplasm. 
Lung sections of the mice treated with the agents
Owing to PA derived from paraquat, we tested the lung toxicity of the treated mice with pathological examination. Compared with the saline group, TPG and PPG groups did not show evidence of pulmonary fibrosis and the capillary congestion was the main change. This indicated that PA indeed accumulated in the lung but could not lead to irreversible lung injury like paraquat. Figure S15 . Flow cytometry analysis of TBLB samples. The TBLB tissues were separated under direct under direct vision and dissociated to single cell suspension. APC channel for TPG and FITC channel for CEA and CK19. The numbers were consistent one-to-one matches between Table S1 and Figure S15 . To assess the efficacies of Gefitinib, PA, PPG, as well as a mixture of PA and Gefitinib, we employed CCK-8 assay to evaluate their inhibition efficacy in PC9 and H1650 cells, respectively. As shown in Figure S16 , the efficacy of PA was not as good as Gefitinib. The CCK-8 results showed that the mixture of PA and Gefitinib could not lead to high PC9 cells inhibition as PPG behaved. But the mixture of PA and Gefitinib caused more inhibition than administeration of PA or Gefitinib alone. H1650 was the resistant cell line to Gefitinib. The mixture of PA and Gefitinib could not result in higher inhibition than PPG. The cell viability treated by the mixture of Gefitinib and PA had no significant difference compared with Gefitinib or PA. The low efficacy of PA resulted from the fact that multiple pathways led to tumor occurrence, and single Akt inhibition could not depress the tumor growth. 
Flow cytometry analysis of TBLB samples
Table of the patients` files
The efficacy assay of control prodrug PCG
To evaluate the efficacy and the response to thiols, we employed CCK-8 assay to test the inhibition rate of PCG. The final concentration was 1 μM and the assay lasted 72 h. PPG was used as a control prodrug. As shown in Figure S17 , PCG could not inhibit much less cell growth than PPG.
The prodrug stability and the release of Gefitinib assay in the presence of albumin
We performed the HPLC experiments to investigate the stability of the prodrug (PPG) in the presence of albumin and to determine the albumin binding rate of prodrug. Bovine serum albumin (BSA, 0.04 g/mL) was prepared in HEPES buffer (10 mM, pH 7.4, 0.5% DMSO, 0.4% Tween 80) at 37°C. And PPG (10 μM) was dissolved in the above solution.
Seven standard samples of PPG in 0.04 g/mL BSA (0.5, 1.0, 2.0, 5.0, 10.0, 15.0 and 20.0 μM) were prepared to generate the calibration curve for linearity of the method. PPG were separated on reversedphase high performance liquid chromatography (RP-HPLC) with a ZORBAX SB-C18 column (4.6×150 mm, 5 μm), acetonitrile/0.15% (v/v) ammonium acetate (adjusted pH 8.0 with ammonium hydroxide) = (85:15, v/v) as mobile phase at a flow rate of 1.0 mL/min, detection wavelength of 310 nm and column temperature of 37°C, injection volume: 20 µL. The peak of PPG appeared at 2.06 min ( Figure S18a) .
To evaluate the stability of the PPG, PPG was dissolved in the 0.04 g/mL BSA solution for 48 h. And the samples were added in the ultrafiltration system (cellulose acetate membrane with 25 KDa molecular weight cut-off) at the time points of 0 h, 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, and 48 h. Centrifugations were performed at 37°C, for 10 min at 4000 rpm, resulting in filtrate. The filtrate was performed RP-HPLC analysis. As shown in Figure S18b , the concentration of PPG in the filtrate didn't change in 48 h. The result indicated that the prodrug PPG was stable in the presence of albumin. The fraction of unbound was determined by the following equation [4] : ƒu = Cu / Ct Where ƒu is the fraction of unbound drug in albumin, Cu is the unbound concentration, and Ct is the total concentration of the analyte in albumin, respectively.
Then the albumin binding rate of prodrug was determined by the ultrafiltration method mentioned above [5] . And the albumin binding rate of prodrug with bovine serum albumin was 78.2 ± 0.5%.
The release of Gefitinib is based on GSH to cleave the disulfide bond. Because the GSH concentration in the plasma was 0.34 ± 0.11 μM [6] , which was unable to induce the rapid release of Gefitinib. As shown in Figure S18a , none Gefitinib was detected through HPLC. Therefore, nearly no Gefitinib was released in albumin condition.
The stability of Azo-BODIPY fluorophore
The Azo-BODIPY fluorophore had been widely used in bioimaging. The stable experiment was carried out to verify the stability of the dye in the testing solution. As shown in Figure S19 , the fluorescent intensity hardly changed under the testing condition within 42 h. 
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